Nurix
The Associate Director of Clinical Biomarkers will lead the development and execution of biomarker strategies to support early-phase clinical programs, advancing patient selection, pharmacodynamic assessments, and mechanistic understanding. This leader will collaborate across research, clinical development, external partners and CROs to integrate biomarker data into clinical plans. The role also involves overseeing assay development and validation and mentoring junior scientists to drive scientific excellence.
Headquarters
Brisbane, California, United States
Company Size
201-500 employees
Founded
2012
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing medicines that harness targeted protein degradation to treat cancer and autoimmune diseases. Using a proprietary platform that combines small-molecule degraders and Degradation Activating Compounds (DACs) to engage E3 ubiquitin ligases and the ubiquitin–proteasome system, Nurix aims to selectively remove disease-causing proteins. The company advances multiple discovery and development programs and collaborates with partners to translate its platform into novel therapies. Their mission, "Medicines to Outmatch Disease," guides efforts to create differentiated, targeted treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Nurix.
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX)
1 month ago